

North Carolina Life Science Investments, Licenses and Grants

January 1, 2008 - December 31, 2008

Total Amount: \$1,182,904,220

Chelsea Therapeutics Raises \$48.9 Million 1/14/2008

Chelsea Therapeutics, a Charlotte-based biopharmaceutical development firm, has raised \$48.9 million through a private stock offering. The company sold 7.4 million shares of common stock at \$6.62.

Investment \$48,900,000

InnerOptic Secures \$370,000 in Funding 1/14/2008

InnerOptic Technology Inc., a Hillsborough-based medical device company, has secured \$370,000 in funding from CatoBio Ventures and an unidentified angel investor. The funds will be used to further develop its InVision System for laparoscopic procedures. InnerOptic hopes to raise an additional \$4.3 million.

Investment \$370,000

UNC/ECU Racial Disparities Program Receives Federal Funding 1/24/2008

The Program in Racial Disparities and Cardiovascular Disease, a collaboration between UNC-Chapel Hill and East Carolina University, will receive \$560,000 in federal funds. The research seeks to further the understanding of how race contributes to differences in health care.

Equity \$560,000

Federal Funding for Collaborative Initiative in Biomedical Imaging 1/24/2008

The Collaborative Initiative in Biomedical Imaging will receive \$984,000 in federal funding to develop noninvasive techniques to follow disease progression for cancer, diabetes and other illnesses.

Grant \$984,000

UNC Medical Receives \$2.4M for Cancer Research 1/24/2008

Federal agencies have awarded \$4 million in funding for three UNC medical research initiatives. Through the largest, the UNC Hospital's Lineberger Comprehensive Cancer Center will receive \$2.4 million for its research to understand the genetics of cancer and develop better treatments.

Grant \$2,400,000

Clinipace Raising \$2.6 Million 1/29/2008

Clinipace Inc., a company located in Research Triangle Park, is raising \$2.6 million. Clinipace was founded five years ago and sells software used in late-stage clinical research.

Equity \$2,600,000

Inclinx Enrolls Frontier Capital in \$10M Expansion Funding 1/29/2008

Inclinx Inc. has raised \$10 million in expansion capital from Charlotte-based Frontier Capital. Inclinx provides clinical research-related offerings as well as strategic medical marketing communications and adherence services to the healthcare industry.

Equity \$10,000,000

TransEnterix Raises \$21M for Non-Invasive Surgical Technology 1/29/2008

Research Triangle Park's, TransEnterix Inc., a company founded by Synecor, has raised \$21 million for the development of novel and less-invasive tools and techniques for high volume gastro-intestinal surgical procedures. Investors include SV Life Sciences, Parish Capital Advisors and Synergy Life Science Partners.

Equity \$21,000,000

Hamner Institute Researcher Receives \$2.1M NIH Grant 2/6/2008

Dr. Yin Chen of the Hamner Institutes for Health Science has been awarded a \$2.1 million grant from the National Institute of Allergy and Infectious Diseases/National Institutes of Health (NIH). Dr. Chen's research focuses on the causes of excessive mucous production which is a major contributing factor to airway obstruction in chronic lung diseases.

Grant \$2,100,000

Filtara Receives NC IDEA Grant 2/13/2008

Filtara received a product development grant from NCIDA . Filtara is a Cary-based developer of small, lightweight, long-lasting portable oxygen concentrator.

Grant

CorePrognostex Receives NC IDEA Grant 2/13/2008

CorePrognostex received a product development grant from NCIDEA. CorePrognostex is a Durham-based developer of a tissue acquisition protocol, a patented stereotactic tissue-holding device, and custom-designed kits that enable uniform collection of high-quality human tissue samples.

Grant

Array BioPharma Opens Morrisville Office 2/20/2008

Array BioPharma, a Colorado company has leased 20,000 square feet in Morrisville, NC at Perimeter Park. Array BioPharma is developing cancer treatments and hopes to test its experimental medicines in the Triangle.

Investment

Novozymes Put \$4M to Laboratory Expansion in Franklinton 2/27/2008

Novozymes is putting \$4 million towards laboratory expansion in Franklinton, NC which will be dedicated to biomass conversion for ethanol. Novozymes is working towards producing ethanol with farm wastes versus corn kernels to prevent production costs of ethanol production from affecting food prices.

Investment \$4,000,000

Siemens to Bring 300 Jobs to Cary, NC 3/3/2008

Siemens Medical Solutions will spend \$60 million to expand its operations in Cary, NC creating 300 new jobs.

Investment \$60,000,000

Chesson Labs Raise \$3.3 Million 3/4/2008

Durham, NC based health-care product company Chesson Labs has raised \$3.3 million in first round funding. The company received funds from numerous angel investors to develop future products and to bring them to market. In addition to a liquid bandage, Chesson is also working on products to treat bites and stings and nail fungus.

Equity \$3,300,000

BD Creates 274 New Jobs with Expansion 3/17/2008

Becton, Dickinson plans to build a new plant in Wilson County and expand its existing Durham County facility. The medical technology company will be creating 274 new jobs in the Triangle area. BD will invest \$134.7 million in the expansion project over the next five years. About 182 of the new jobs will be located in Durham while the rest will be in Wilson.

Investment \$134,700,000

Scynexis Receives another \$13.5M in Venture Capital 3/31/2008

Durham-based drug research firm, Scynexis has closed on \$13.5 million in a Series C round of funding. Investors include Burrill & Co., Alta Partners, SGAM and Ventech. Scynexis offers a proprietary compound library purification, analytical tools and strong medicinal chemistry expertise.

Equity \$13,500,000

RTP's Kryosphere Secures \$1M in Funding 3/31/2008

Kryosphere, a biostorage startup company in RTP, has secured \$1 million in angel funding and debt financing. Kryosphere offers biorepository and logistical management services to maintain and protect biospecimen samples.

Equity \$1,000,000

BioDelivery Sciences Receives \$2.5 Million 4/7/2008

BioDelivery Sciences International has received a \$2.5 million milestone payment from Meda AB. Meda AB has filed for approval for BEMA Fentanyl in Germany, a pain medicine for cancer patients experiencing breakthrough pain.

License \$2,500,000

Five New SBIR Grants Awarded to Affinergy 4/7/2008

Affinergy has received five Small Business Innovation Research (SBIR) grants. One of the five grants includes a Phase 2 award of nearly \$2.1 million, funded by the National Institute of General Medical Sciences. The other four grants are for Phase 1 programs. Collectively, all five grants exceed \$3.1 million. Affinergy produces "biolinker" coatings that work to accelerate the healing and recovery process after surgery.

Grant \$3,100,000

ArtusLabs Lands \$2.6M in Financing 4/15/2008

ArtusLabs, a startup that develops software for the pharmaceutical and biotechnology industry, has landed \$2.6 million in new financing. Hatteras Venture Partners and Southern Capitol Ventures led the Series A round. ArtusLabs plans to use the funding to expand its software offerings and marketing efforts.

Equity \$1,600,000

PPD Adds 300 New Jobs 4/15/2008

PPD Inc. will establish a 300 employee operation in Kannapolis, NC at the North Carolina Research Campus. The jobs will be created over the next three years. PPD conducts clinical trials for drug makers and is based in Wilmington.

Investment

Metabolon Raising \$5 Million 4/15/2008

Metabolon has drawn down \$3 million of a \$5 million raise. The investors include the Aurora Funds, The Trelys Funds, Sevein Fosen Funds, and Harris & Harris Group. Metabolon develops diagnostic products for diabetes, ALS, and prostate cancer.

Equity \$5,000,000

Novozymes Expanding in Franklinton 4/28/2008

Novozymes is investing over \$26 million for expansion of its production, labs and office facilities in Franklinton, NC. The expansion is expected to add as many as 50 new jobs at the site.

Investment \$26,000,000

Tryton Medical Relocates to RTP & Raises \$14M 4/28/2008

Tryton Medical, a developer of stent technology, is moving its headquarters to Research Triangle Park, NC. Tryton, originally of Massachusetts, closed on \$14 million in venture capital earlier this month. Tryton announced that J. Greg Davis, a veteran Guidant and Eli Lilly executive, is its new president and chief executive officer. PTV Sciences and RiverVest Venture Partners led the \$14 million Series C venture capital round.

Equity \$14,000,000

Institute for Regenerative Medicine Receives Federal Grant 4/28/2008

The Institute for Regenerative Medicine at Wake Forest University Baptist Medical Center has been awarded \$42.5 million over five years to co-lead one of two academic groups that will form the Armed Forces Institute of Regenerative Medicine (AFIRM). The consortiums, working with the U.S. Army Institute of Surgical Research, will use the science of regenerative medicine to develop new treatments for wounded soldiers. AFIRM will be dedicated to repairing battlefield injuries through regenerative medicine to restore or replace damaged tissue and organs. Therapies developed by AFIRM will also benefit the civilian population with burns or severe trauma.

Grant \$42,500,000

Aldagen Raises \$18.4 Million

4/28/2008

Aldagen has raised \$18.4 million in a private round of financing. Investors include Intersouth Partners, Tullis-Dickerson, Harbert Venture Partners and The Aurora Funds. Aldagen plans to use the proceeds to advance the development of its four clinical-stage product candidates and for general corporate purposes. Aldagen is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs.

Equity \$18,400,000

Argos Therapeutics Secures \$35.2M in New Funding

4/28/2008

Argos Therapeutics has secured \$35.2 million in new venture financing. The company, formerly known as Merix, is developing drug therapeutics based on the human immune system. Argos has several clinical trials under way for renal cell carcinoma and one for an HIV and cancer immunotherapy. Argos plans to use the funds for further trials of its leading candidates and further development of its protein immunology program that is being prepared for initial human clinical trial.

Equity \$35,200,000

Pozen Receives \$20M From GSK For Migraine Drug

4/30/2008

Pozen has received \$20 million from its drug development partnership with GlaxoSmithKline. The migraine drug Treximet was approved by the FDA and triggered a \$20 million milestone payment to Pozen by GSK. Pozen has already been paid more than \$30 million in development and milestone payments from GSK. Treximet includes Imitrex in combination with an anti-inflammatory pain reliever. Pozen's proprietary technology is used to combine the drugs.

License \$20,000,000

CivaTech Oncology Raises \$1M in B Round Financing

5/1/2008

CivaTech Oncology, Inc., has raised \$1 million in a Series B private financing round. CivaTech is an early stage company developing treatment for prostate cancer with a novel medical device. CivaTech Oncology's new device should provide more uniform and consistent radiation delivery to patients.

Equity \$1,000,000

NC's Targacept Receives \$500K Milestone Payment

5/7/2008

Targacept has triggered a \$500,000 milestone payment from development partner GlaxoSmithKline. Targacept announced its lead compound for a smoking-cessation treatment which triggered the payment. Targacept says the compound manipulates neuronal nicotinic receptor proteins and may counteract the addictive qualities of nicotine.

License \$500,000

Inspire Pharma Sees \$1.25M in Milestone Pay

5/20/2008

Inspire Pharmaceuticals has received \$1.25 million from its dry eye partner, Santen Pharmaceutical Co., related to the completion of Santen's Phase 3 testing of diquafosol tetrasodium, referred to as DE-089, for treatment of dry eye. Santen announced that it expects to file an application by the end of June 2008 for marketing approval in Japan. Inspire is a biopharmaceutical company dedicated to discovering, developing and commercializing prescription pharmaceutical products for diseases in the ophthalmic and respiratory areas.

License \$1,250,000

Duke Awarded \$6M Grant

5/21/2008

The latest \$6 million grant from the Pediatric Brain Tumor Foundation is doubling the dollar commitment to its research institute at Duke University to \$12 million. Duke and the PBTF are working together in an effort to improve treatments of the tumors. "The goal of this grant is to translate our understanding of childhood brain tumors into novel, less invasive treatment methods," said Dianne Traynor, PBTF Director of Research Funding and Advocacy.

Grant \$6,000,000

Proventys Lands \$5.65M in Funding

5/21/2008

Proventys Inc., a personalized medicine knowledge service provider, has secured \$5.65M in Series A1 financing. Life sciences-focused venture capital firm Burrill & Company led the investment in Proventys. Timothy Thompson, formerly managing director of business development at Aetna, joined the company as president and CEO.

Equity \$5,600,000

UNC Awarded \$19.9M Grant for Study of Stroke Prevention

5/27/2008

The National Institute for Neurological Disorder and Stroke has awarded the University of North Carolina School of Medicine a \$19.9 million grant over five years to fund a study which explores whether brain bypass surgery can prevent stroke. The study will include patients at 41 medical centers in the U.S. and Canada. Researchers will see if an artery that supplies blood to the scalp can be used to bypass blockages in a major neck artery that supplies blood to the brain.

Grant \$19,900,000

NCSU Receives \$1.8M to Study Links Between Pollution & Health

5/28/2008

Researchers at North Carolina State University have won \$1.8 million in federal grants in order to establish more definitive statistical links between pollution and diseases such as asthma and heart disease. The grants for the statistical analysis came from the National Institutes of Health and the Environmental Protection Agency. The NIH grant, worth \$1,086,133, covers three years. The EPA grant is \$839,439 over three years.

Grant \$1,800,000

UNC Lands \$61M CTSA Grant

6/2/2008

The University of North Carolina at Chapel Hill has landed a \$61 million, five-year grant from the National Institutes of Health. The grant is part of NIH's Clinical and Translational Science Awards program. The program is an effort dedicated to moving research from university labs into the community at large. The NIH grant will help fund the new Translational and Clinical Sciences Institute, which will focus on bringing research from the lab to the home.

Grant \$61,000,000

Merck Invests \$300M in Durham Expansion Adds 150 Jobs

6/30/2008

Merck plans to expand its vaccine manufacturing facility in Durham by investing \$300 million and creating 150 new jobs. Merck has started construction of its 235,000 square foot plant in 2004 and has completed it this year.

Investment \$300,000,000

Arbovax Gets \$1.43M in First Round 6/30/2008

Arbovax Inc., a vaccine developer has closed its Series A round with a total of \$1.43 million in investments. Arbovax will use the investments to move forward with its Dengue Fever Virus program. Arbovax is developing a novel technology to develop vaccines against insect borne viruses.

Equity \$1,430,000

Patheon Selects RTP for Headquarters 6/30/2008

Research Triangle Park, North Carolina, has been chosen as the new global headquarters for Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry.

Investment \$437,500

Wake Forest Get Tissue Manufacturing Grant 7/1/2008

Wake Forest University's Institute for Regenerative Medicine has received a \$250,000 grant from the Bank of America Charitable Foundation to support the construction of a Good Manufacturing Practices facility where engineered organs and tissues will be built.

Grant \$250,000

Danish Company Cheminova to Move Headquarters to RTP 7/1/2008

Cheminova, a Danish company which produces insecticides and herbicides is moving it's U.S. headquarters to Research Triangle Park, NC. Cheminova will begin its move in August and expects 18 employees in September. The company is moving its headquarters from Wayne, NJ.

Investment \$146,080

Syngenta Expanding in RTP 7/1/2008

Syngenta is expanding its operations to One Park Drive in Research Triangle Park, NC. The Switzerland-based Syngenta houses its global biotechnology research and development headquarters on Cornwallis Road in RTP. That current location employs 300 workers. About 80 administrative workers will be shifted to the new building on One Park Drive to make room for additional lab space at the Cornwallis location.

Investment \$671,640

RTI Gets \$5M for FDA Food Safety 7/2/2008

RTI International has won a \$5 million, five-year contract with the Food and Drug Administration to help improve food safety. RTI will research which food-related threats are highest to the public, identify research priorities and select strategies to achieve the greatest reductions to health risks linked to fresh produce and shellfish. Emphasis will be placed on microbial and chemical hazards in the food industry.

Grant \$5,000,000

Addrenex Lands Drug Development Deal 7/2/2008

Addrenex has landed another drug development deal with Sciele Pharma that could potentially be worth up to \$27 million. Sciele Pharma and Addrenex will partner to develop a compound that could treat hypertension.

License \$0

TheraLogics Wins NIH Grant 7/7/2008

TheraLogics, a UNC Chapel Hill spinout, has received a two year \$800,000 National Institutes of Health grant to study treatments for “graft versus host disease” which is a common side effect of bone marrow and cord blood transplants.

Equity \$800,000

UNC Gets \$3.4M for Chemical Impact on Environmental Health 7/7/2008

The University of North Carolina at Chapel Hill has been awarded a \$3.4 million grant by the United States Environmental Protection Agency (EPA) for computational toxicology and bioinformatics. Computational toxicology predicts adverse effects of drugs and chemicals on human health and the environment. Over the next four years, the grant will go towards the creation of the Carolina Center for Computational Toxicology.

Grant \$3,400,000

Excela PharmaSci to Build New Plant in Caldwell County 7/7/2008

A Virginia based company, Excela PharmaSci, plans to build a new pharmaceutical plant in Caldwell County in Lenoir. The plant will create 55 new jobs. Galexe Pharma Sciences, a subsidiary of Excela, will invest \$8.6 million over the next three years in the new facility. Excela chose to build in North Carolina because of the One North Carolina Fund grant of \$250,000. Excela had considered building the plant in India or Virginia, before deciding on North Carolina.

Investment \$8,600,000

CoLucid Pharmaceuticals Closes on \$25M Round 7/7/2008

CoLucid Pharmaceuticals Inc. has closed a \$25 million Series B financing round. The financing will be used to further develop a unique migraine compound, COL-144, and to advance novel chemical entities that target neurological and psychiatric disorders. COL-144 is designed to work effectively without vasoconstriction. CoLucid is also working on a drug for the treatment of sleep/wake disorders by using a drug that provides amphetamines without the side effects of addiction or hyperactivity.

Equity \$25,000,000

NCSU Vet School Receives \$625,000 Gift from Novartis 7/17/2008

The North Carolina State University Veterinary School has received a \$625,000 gift from international drug giant, Novartis. The funds will be used for clinical trials program at the Center for Comparative Medicine and Translational Research. The grant will be used over the course of five years and will go towards lab space, equipment, a research technician, and a clinical trials veterinarian.

Grant \$625,000

Slate Pharmaceuticals Raises \$5 Million 7/17/2008

Durham startup company, Slate Pharmaceuticals, has closed on nearly \$5 million in funding. The company makes implantable hormones and markets Testopel, an implantable testosterone pellet. Slate is also testing a menopause hormone treatment.

Equity \$5,000,000

Athenix Raises \$10M for Crop Protection Products

7/24/2008

Athenix has raised a new \$10 million round from investors including Hunt Ventures, Intersouth Partners and Polaris Venture Partners. The company produces crops with enhanced traits such as tolerance to herbicides and resistances to pests. Athenix will apply its expertise in microbial screening and genomics to facilitate gene discovery intended to help protect crops such as cotton, soybeans and corn against a common class of insects known as Hemipterans. Hemipteran insects include Lygus, a pest of cotton, and stinkbug, a pest of soybean.

Investment \$10,000,000

UNC School of Medicine Professor Receives \$400,000 Grant

8/4/2008

Arjun Deb, an assistant professor at the University of North Carolina at Chapel Hill, has received a grant of \$400,000 to study cardiac stem cells and the role they may play in the aging cardiac system. The grant was awarded by the Ellison Medical Foundation and will be spread over four years.

Grant \$400,000

RemedEase Stops Nose Bleeds With First Round

8/18/2008

Durham-based RemedEase Inc. has closed on its first round of \$500,000 for its patented advanced technology to stop nosebleeds. RemedEase will use the funds to support product development, begin the FDA approval process and expand marketing initiatives.

Equity \$500,000

UNC Spin-Off Gets \$2M for Cancer Treatment

9/9/2008

A UNC Chapel Hill spin-off company, Morphormics Inc., was awarded \$2 million to commercialize new technology for radiation treatment for prostate cancer. The National Cancer Institute awarded the grant as a part of a Small Business Innovation Research program.

Grant \$2,000,000

NC A&T Receives National Science Foundation Funding

9/9/2008

North Carolina A&T State University in Greensboro has become the first historically black college to receive National Science Foundation funding for a research center. The university will receive more than \$18 million over the next five years to fund the Engineering Research Center for Revolutionizing Metallic Biomaterials.

Grant \$18,000,000

Wake Forest Gets \$9.3M Federal Grant

9/12/2008

Wake Forest researchers received a federal grant to study ways of preventing heart disease. The Lipid Sciences Research Program at Wake Forest University School of Medicine has been awarded a grant renewal of more than \$9 million to define the aspects of blood lipoproteins that are critical in preventing coronary heart disease. The grant is from the National Heart, Lung and Blood Institute, of the National Institutes of Health.

Grant \$9,300,000

Affinergy Receives \$3.6M in Federal Grants 9/12/2008

Duke spinout, Affinergy, has landed a \$3.6 million federal grant to be used in developing its proprietary medical-device delivery technology. Affinergy produces “biolinker” coatings that adheres to biomaterials during orthopedic and cardiovascular procedures. This coating accelerates healing and recovery after surgery.

Grant \$3,600,000

UNC-CH Researchers get \$800K NIH Grant 9/23/2008

UNC Chapel Hill’s associate professor of biochemistry, Brian Strahl, has received an \$800,000 grant from the National Institutes of Health to research the so-called “histone code” which are proteins that help package DNA.

Grant \$800,000

NC’s Zen-Bio Gets \$200K SBIR Grant 9/23/2008

Zen-Bio has won an SBIR grant from the National Institutes of Health to develop a better way to isolate and culture breast cancer cells.

Equity \$200,000

BioMedomics Lands Phase II SBIR Contract 10/1/2008

BioMedomics has received a \$750,000 Phase II SBIR grant from the National Institutes of Health. BioMedomics develops medical diagnostic tools for use in the fast growing field of personalized medicine.

Grant \$750,000

ZenBio Receives \$1.38M Grant for Diabetes and Obesity 10/1/2008

ZenBio, a life-science company, has landed a \$1.38 million federal grant for the commercialization of means of combating Type II diabetes and obesity. The company focuses on tissue engineering such as stem cells. The project is focused on cells linked to insulin disposal and resistance in skeletal muscle and adipose tissue.

Grant \$1,380,000

RTI Gets \$7.2M to Evaluate Flu Treatments 10/1/2008

RTI has secured a contract funded by the US Centers for Disease Control to evaluate the effectiveness of neuraminidase inhibitors in fighting the flu. The study will evaluate treatment in older adults.

Grant \$7,200,000

Novozymes Lands \$12.3M Department of Energy Biofuels Contract 10/10/2008

Novozymes expects to use \$12.3 million in federal funding to enhance the performance of the enzymes that are used to produce cellulosic ethanol. Novozymes seeks to double the performance of the current enzyme used to produce ethanol.

Grant \$12,300,000

UNC Launches \$7M Muscular Dystrophy Research Center 10/10/2008

A new muscular dystrophy research center will be created at UNC Chapel Hill as a part of a \$7 million grant from the National Institutes of Health. The center will be one of the seven that the NIH has established.

Grant \$7,000,000

Biolex Therapeutics Gets New \$60 Million Round 10/10/2008

Biolex Therapeutics has raised a \$60 million Series D funding led by Clarus Ventures with OrbiMed Advisors and return backers. Biolex is a clinical-stage biopharmaceutical company that uses its patented LEX SystemSM to develop hard-to-make therapeutic proteins to optimize monoclonal antibodies. Biolex uses Duckweed to make the proteins and monoclonal antibodies.

Investment \$60,000,000

UNC Scientist Awarded \$2.9M Grant 10/16/2008

Dr. Andrew Olshan of UNC-Chapel Hill has been awarded a grant worth \$2.9 million from the National Cancer Institute. Dr. Olshan is professor and chair of the epidemiology department and will study the causes of neuroblastoma. Neuroblastoma develops from the nerve cells and is the most common cancer in babies and children under 5 years old.

Grant \$2,900,000

CeNeRx Raises \$15M in Second Round Funding 10/17/2008

CeNeRx BioPharma has closed on a Series B round of venture funding, and is ready to go to Phase II tests with the additional \$15 million in funding. The new funds will be used for the next phase of trials for Tyrina, a drug intended to treat major depressive disorder. Investors include Pappas Ventures, Aisling Capital and L Capital Partners.

Investment \$15,000,000

Merck to Invest up to \$750 Million in NC 10/17/2008

Merck has committed to investing up to \$750 million to complete construction of a new vaccine plant in Durham, North Carolina. The company has previously announced \$700 million of investments at the Durham site. Merck says that further expansion in the area is likely.

Investment \$50,000,000

UNC-CH, ECU & Rex Team Up for \$2M Cancer Research 10/27/2008

Researchers at University of North Carolina Chapel Hill, East Carolina and Rex Hospital are teaming up for a research project involving a dangerous side effect of cancer treatment. A five-year \$2 million grant from NIH will fund the project which investigates a potential early indicator for venous thromboembolism. The condition creates clots in the legs that can break loose and travel to the lungs.

Grant \$2,000,000

Dara Biosciences Raises \$2.25M in Stock Offerings 10/28/2008

Dara Biosciences has raised \$2.25 million through a discounted sale of stock.

Equity \$2,250,000

UNC-CH gets \$3.25M in Additional Funding 12/3/2008

The University of North Carolina at Chapel Hill will receive an additional \$3.25 million in funding over the next five years for an autism study.

Grant \$3,250,000

Tengion Gets \$21M Round 12/3/2008

Tengion has raised \$21 million in its second round. The company's pilot manufacturing is in Winston Salem. The company focuses on developing, manufacturing and commercializing human neo-organs and neo-tissues using an autologous organ regeneration platform.

Investment \$21,000,000

Duke Receives \$3M Gates Grant for HIV Study 12/3/2008

The Bill & Melinda Gates Foundation has awarded Duke University a \$3 million grant for a study in why some individuals can resist HIV.

Grant \$3,000,000

Targacept Gets \$2M for Another Compound 12/12/2008

Targacept will further test a compound jointly developed by AstraZeneca and Targacept. The decision has triggered a \$2 million milestone payment to Targacept.

License \$2,000,000

Oncoscope Lands First Venture Funding 12/12/2008

Oncoscope, a Durham based medical startup, has landed its first venture funding. Oncoscope focuses on early cancer detection technology using optical technology.

Investment

Parion receives \$5M from Gilead Sciences 12/12/2008

Parion Sciences, a drug research firm, has received a \$5 million milestone payment from Gilead Sciences. Parion is a startup company utilizing technology licensed from UNC-Chapel Hill.

License \$5,000,000

Parion Sciences gets \$850K Biodefense Grant 12/24/2008

NC-Based Parion Sciences has won a NIH grant for \$850,000 for its development for treatments for diseases resulting from the failure of the body's mucosal defenses. The grant is to advance the development of safe and effective medical treatments to help prevent injury from inhaling radioactive particles.

Grant \$850,000

NCIDEA Awards Startup Grant to InnerOptic 12/24/2008

Hillsborough-based InnerOptic was awarded a \$44,965 NCIDEA grant for its medical device utilizing visualization technology to assist in removal of surface materials from tumors.

Grant

NCIDEA Awards Startup Grant to BioMedomic	12/24/2008
--	------------

RTP-based BioMedomics has received an NCIDEA grant of \$45,000. The company is developing point of care diagnostics that can be used in the field and are done at a molecular level.

Grant

Cerene Biomedics wins \$100K SEBIO Competition	12/29/2008
---	------------

Duke spinoff Cerene Biomedics has won the \$100,000 SEBIO Competition. Cerene Biomedics is developing an implantable medical device to prevent epileptic seizures.

Other	\$100,000
-------	-----------

AlphaVax gets \$20M for Herpes Vaccine	12/30/2008
---	------------

Novartis has said that it is paying AlphaVax \$20 million upfront to secure the right to a developmental vaccine for CMV, a virus of the herpes family.

License	\$20,000,000
---------	--------------

Total Amount:	\$1,182,904,220
----------------------	------------------------

For more information, contact Sam Taylor, President
North Carolina Biosciences Organization
P.O. Box 14354, Research Triangle Park, NC
(919) 281-8960; staylor@ncbioscience.org